Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet. 2011;377:1264–75.

Article  PubMed  PubMed Central  Google Scholar 

Ferreira-Coimbra J, Sarda C, Rello J. Burden of community-acquired pneumonia and unmet clinical needs. Adv Ther. 2020;37:1302–18.

Article  PubMed  PubMed Central  Google Scholar 

Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019;380:651–63.

Article  CAS  PubMed  Google Scholar 

Tsunoda H, Okami Y, Honda Y, Shiroshita A, Kataoka Y, Tsujimoto Y, et al. Effectiveness of angiotensin converting enzyme inhibitors in preventing pneumonia: a systematic review and meta-analysis. J Gen Fam Med. 2022;23:217–27.

Article  PubMed  PubMed Central  Google Scholar 

Alexander DP, Nickman NA, Chhibber A, Stoddard GJ, Biskupiak JE, Munger MA. Angiotensin-converting enzyme inhibitors reduce community-acquired pneumonia hospitalization and mortality. Pharmacotherapy. 2022;42:890–7.

Article  CAS  PubMed  Google Scholar 

Grilo A, Sáez-Rosas MP, Santos-Morano J, Sánchez E, Moreno-Rey C, Real LM, et al. Identification of genetic factors associated with susceptibility to angiotensin-converting enzyme inhibitors-induced cough. Pharmacogenet Genom. 2011;21:10–7.

Article  CAS  Google Scholar 

Caldeira D, Alarcão J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260.

Article  PubMed  PubMed Central  Google Scholar 

Liu CL, Shau WY, Wu CS, Lai MS. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients. J Hypertens. 2012;30:2223–9.

Article  CAS  PubMed  Google Scholar 

Uemura R, Hieda M, Maeda M, Murata F, Fukuda H. Risk of pneumonia-related hospitalization after initiating angiotensin-converting enzyme inhibitors compared with angiotensin II receptor blockers: a retrospective cohort study using LIFE Study data. Hypertens Res. 2024. https://doi.org/10.1038/s41440-024-01768-7. Epub ahead of print.

Matsuzawa Y, Kimura K, Ogawa H, Tamura K. Impact of renin-angiotensin-aldosterone system inhibitors on COVID-19. Hypertens Res. 2022;45:1147–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–80.e8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, et al. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol. 2011;225:618–27.

Article  PubMed  Google Scholar 

Shin J, Toyoda S, Nishitani S, Onodera T, Fukuda S, Kita S, et al. SARS-CoV-2 infection impairs the insulin/IGF signaling pathway in the lung, liver, adipose tissue, and pancreatic cells via IRF1. Metabolism. 2022;133:155236.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pedrosa MA, Valenzuela R, Garrido-Gil P, Labandeira CM, Navarro G, Franco R, et al. Experimental data using candesartan and captopril indicate no double-edged sword effect in COVID-19. Clin Sci. 2021;135:465–81.

Article  CAS  Google Scholar 

Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet Respir Med. 2021;9:863–72.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsukamoto S, Wakui H, Azushima K, Yamaji T, Urate S, Suzuki T, et al. Tissue-specific expression of the SARS-CoV-2 receptor, angiotensin-converting enzyme 2, in mouse models of chronic kidney disease. Sci Rep. 2021;11:16843.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962.

Article  PubMed  PubMed Central  Google Scholar 

Matsuzawa Y, Ogawa H, Kimura K, Konishi M, Kirigaya J, Fukui K, et al. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. Hypertens Res. 2020;43:1257–66.

Article  CAS  PubMed  Google Scholar 

Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648–54.

Article  CAS  PubMed  PubMed Central  Google Scholar